A share price of Affimed N.V. [AFMD] is currently trading at $0.59, up 5.02%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AFMD shares have gain 6.68% over the last week, with a monthly amount glided 3.47%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 8, January 2024, Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer. In a post published today on Yahoo Finance, Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohort.
From an analyst’s perspective:
Affimed N.V. [NASDAQ: AFMD] stock has seen the most recent analyst activity on December 12, 2022, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $6. Previously, Stifel downgraded its rating to Hold on October 10, 2022, and dropped its price target to $2. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $7 on March 31, 2022. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $12 as its price target on February 23, 2022. Truist started tracking with a Buy rating for this stock on October 21, 2021, and assigned it a price target of $10. In a note dated September 30, 2021, Stifel initiated an Buy rating and provided a target price of $12 on this stock.
Affimed N.V. experienced fluctuations in its stock price throughout the past year between $0.22 and $1.11. Affimed N.V. [NASDAQ: AFMD] shares were valued at $0.59 at the most recent close of the market.
Analyzing the AFMD fundamentals
Trailing Twelve Months sales for Affimed N.V. [NASDAQ:AFMD] were 19.87M which represents -85.76% decline. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5541 points at the first support level, and at 0.5205 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6082, and for the 2nd resistance point, it is at 0.6287.
Affimed N.V. [AFMD] reported earnings per share of -$0.17 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.2/share, meaning a difference of $0.03 and a surprise factor of 15.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.21 per share as compared to estimates of -$0.2 per share, a difference of -$0.01 representing a surprise of -5.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Affimed N.V. [NASDAQ:AFMD] is 3.70. Further, the Quick Ratio stands at 3.67, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 4.42, the price to book ratio is 1.08.
